Management of de novo metastatic breast cancer (dnMBC) traditionally prioritizes palliative care. However, clinicians increasingly consider oligometastatic breast cancer treatment options like surgery and local ablation for potential survival gains. A recent large-scale study published in JAMA Surgery investigated whether these aggressive interventions actually improve overall survival (OS) for patients with single-site disease.

The researchers conducted a retrospective cohort study using data from the National Cancer Database spanning 2010 to 2020. They analyzed over 22,400 patients diagnosed with single-site oligometastatic dnMBC who received systemic therapy. Specifically, the team compared four strategies: no locally ablative therapy (NLT), primary breast tumor resection only (BR), metastatic site ablative therapy only (MT), and a combination of both (BR+MT).

Evaluating Oligometastatic Breast Cancer Treatment Benefits

The results revealed that bone-only metastases occurred most frequently, appearing in nearly 69% of the cohort. Interestingly, locally ablative therapies remained relatively uncommon in clinical practice. For instance, only 6.4% of patients received both primary tumor resection and metastatic site ablation. Furthermore, the analysis showed that older age and certain clinical factors significantly influenced the choice of treatment strategy.

Moreover, multivariable modeling allowed the team to estimate the association between these treatments and overall survival. Consequently, the findings provide a clearer picture of how local interventions might supplement standard systemic therapy. Physicians should carefully weigh these options within a multidisciplinary framework to optimize patient outcomes. Additionally, prospective trials remain necessary to confirm these survival benefits across diverse patient populations.

Frequently Asked Questions

What is oligometastatic breast cancer?

Oligometastatic breast cancer refers to a stage where the cancer has spread to a limited number of sites, typically five or fewer, rather than extensive systemic involvement.

Does surgery always improve survival in metastatic breast cancer?

While some studies suggest a benefit in specific subgroups, surgery is not yet a universal standard for all metastatic cases. Decisions depend on factors like the site of spread and response to systemic therapy.

Which metastatic site was most common in this study?

In this large-scale cohort, bone-only metastases were the most common, accounting for approximately 68.8% of the patients analyzed.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any medical concerns. Refer to the latest local and national guidelines for clinical practice.

References

Nierenberg TC et al. Locally Ablative Therapies in Oligometastatic Breast Cancer. JAMA Surg. 2026 Mar 04. doi: 10.1001/jamasurg.2026.0098. PMID: 41779401.

Pujari AK et al. Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and Metastasis Directed Radiotherapy. Am J Clin Oncol. 2024 Dec;47(12):552-558.

Saeed H et al. Local therapies for managing oligometastatic breast cancer: a review. Ann Palliat Med. 2022;11(3):1145-1159.